Latest Stock Market News

Nazara Technologies COO Sudhir Kamath will step down on April 1 after a two-and-a-half-year tenure. Despite an increase in revenue, the company saw a 53% YoY decline in net profit for Q3FY25. Shares of Nazara Technologies have declined 7% in the last three months but have gained 81% over the past two years.

Bharat Electronics Ltd secures a significant Rs 2,463 crore contract to supply Ashwini Radars to the Indian Air Force, developed in collaboration with DRDO. The new contract increases BEL s total order inflow for the fiscal year to Rs 17,030 crore, highlighting its strong growth and position as a key defense supplier.

Shares of Coromandel International will be in focus after acquiring a 53% stake in NACL Industries for Rs 820 crore. They plan an open offer for an additional 26% stake. The acquisition boosts Coromandel’s crop protection business and expands its product range. The transaction positions Coromandel as a key player in the Indian agrochemical market.

Blackstone plans significant expansion in India, covering private equity, real estate, technology, data centres, and healthcare. The company aims to build $100 billion worth of businesses. Founder Stephen Schwarzman highlights India s strong growth, young population, and supportive government as key factors driving these ambitions. This will significantly enhance Blackstone s market presence in India.

BEML announced in an exchange filing that it has entered into a non-binding Memorandum of Understanding (MoU) with Siemens India to jointly explore opportunities in the semi-high-speed and suburban passenger train segments, as well as in the metro and commuter rail markets.

On Wednesday, Parliament revealed that state-owned telecom companies BSNL and MTNL have generated a total revenue of Rs 12,984.86 crore through the monetization of assets, including land, buildings, towers, and fiber, since 2019.

ICICI Securities has upgraded Sun Pharmaceutical Industries to Buy with a revised target price of Rs 1895. Sun Pharma, a leading company in the Pharmaceuticals sector, has reported significant income and profit growth. The company s strategic acquisitions and upcoming drug launches are expected to boost its specialty portfolio, despite a recent stock correction.

Sunil Koul, Emerging Market Equity Strategist at Goldman Sachs, forecasts the Nifty to be range-bound at 23,000 in the next three months due to global uncertainties, particularly US tariffs. However, with an anticipated 12% earnings growth, he projects a 13% upside to 25,500 over 12 months. Koul emphasizes investing in quality companies with resilient earnings and strong fundamentals.

Trading below the 200 DMA is considered a negative signal as it indicates the stock is below its long-term trend line.